<DOC>
	<DOCNO>NCT00791401</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics single oral dose 3 mg extend release paliperidone ( ER OROSÃ ' paliperidone ) patient vary degree renal impairment ( mild , moderate , severe ) , compare patient normal renal function . Secondary objective include assess disposition ( + ) ( - ) enantiomer mean enantioselective liquid chromatography mass spectrometry assay , determine plasma protein bind enantiomer patient impaired renal function , compare patient normal renal function , evaluate tolerability safety profile ER OROS paliperidone patient vary degree renal impairment ( mild , moderate , severe ) compare patient normal renal function .</brief_summary>
	<brief_title>A Study Pharmacokinetics ER OROS Paliperidone Volunteers With Normal Impaired Renal Function</brief_title>
	<detailed_description>This single dose , parallel group , open-label , 2 center pharmacokinetic study , consist pretreatment ( screen ) period 1 3 week , open label treatment period ( single dose ER OROS paliperidone Day 1 , end study procedure discharge end Day 6 ) . All patient screen Day 21 Day 1 renal function . On Day 1 , patient receive single oral dose 3 mg ER OROS paliperidone undergo 120 hour follow serial blood collection pharmacokinetics , safety tolerability assessment . Patients discharge give pharmacokinetic blood sample complete end study assessment morning Day 6 . Group match apply renal function group reduce bias increase comparability age , weight , gender , ethnicity . This study aim compare pharmacokinetics safety profile ER OROS paliperidone patient vary degree renal impairment normal patient . 3 mg oral ER OROS paliperidone</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>All patient : A body mass index ( weight [ kg ] /height ( ) ² ) range 18.0 32.0 kg/m² , inclusive Patients normal renal function : Healthy basis prestudy physical examination , medical history , 12lead electrocardiogram ( ECG ) , blood hematology biochemistry test , urinalysis carry within 3 week study drug administer . Normal renal function Agerelated normotensive screening , supine ( 5 minute ) blood pressure range 95 160 mmHg systolic , inclusive , 55 95 mmHg diastolic , inclusive , screen study drug administration Demographically comparable group renal impairment respect age ( ±10 year ) , weight ( ±20 % ) , gender , ethnicity Patients impaired renal function : Has CrCl &lt; 80 mL/min Severity renal disease stable : No significant change renal function evidence serum creatinine value within ±20 % last determination , obtain within least 2 month study entry Is stable dose medication and/or treatment regimen renal impairment 2 month study . Patients stable cardiovascular disease include hypertension control stable dose medication least 2 month enrollment , provide investigator feel condition interfere result study . Patients abnormal ECG change consider investigator insignificant clinically compatible patient 's renal impairment may include Patients stable dose thyroid hormone replacement therapy , least 3 month enrollment , may enrol , provide patient ' condition interfere result study Patients mild , stable , chronic degenerative joint disease may enrol Patients concomitant medication treat underlying disease state medical condition relate renal insufficiency may enrol study , except specifically exclude name pharmacological class . Patients normal renal function : Has significant history presence hematologic , gastrointestinal , renal , hepatic , cardiovascular , pulmonary , metabolic , neurologic , psychiatric disease , relevant history drug allergy , history congenital hereditary kidney disease ( include polycystic kidney disease ) , history nephrectomy Used prescription nonprescription medication ( herbal supplement include ) within 21 day administration study drug except paracetamol ( acetaminophen ) , hormonal contraceptive , replacement therapy Patients impaired renal function : Is end stage renal disease , require dialysis , acute unstable and/or significant untreated medical illness ( e.g. , infection , unstable angina ) , abnormality medical history , physical examination , ECG , laboratory result , opinion investigator , may affect safety patient ( e.g. , myocardial infarction , conduction defect [ e.g. , QTc interval &gt; 450 msec men , &gt; 470 msec woman ] , atrial ventricular arrhythmia , coronary artery disease , congestive heart failure , valvular disease , peripheral vascular disorder , stroke , hematologic , pulmonary , neurologic , hepatic , psychiatric , metabolic endocrine disturbance , inadequate nutritional status , history uric acid stone disease ( last 5 year recurrence ) , uricosuria , current hyperuricemia serum uric acid &gt; =10 mg/dL , uncontrolled Type 1 2 diabetes , renal transplant , systemic lupus erythematosus , renal carcinoma , moderate severe uncontrolled hypertension , define DBP &gt; =105 mmHg and/or SBP &gt; =180 mmHg ( patient stable mild hypertension control constant regimen last 2 month may enrol ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mood disorder</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>ER OROS Paliperidone</keyword>
</DOC>